Superworth

Gilead Sciences price to free cash flow GILD

Market value divided by free cash flow over the last twelve months, since 2010.

Today, Oct 23, 2026
14.9×
10-year median
10.9×
Against its 10-year history
88th
percentile: 0 is its lowest day, 100 its highest
10-year range
5.0× to 21.0×
Peer median
22.3×

Gilead Sciences' price to free cash flow is 14.9× as of Oct 23, 2026.

That is above its ten-year median of 10.9×, higher than on 88% of days in the last ten years.

Over that time it ranged from 5.0× in Feb 2017 to 21.0× in Feb 2026.

The median for 8 large drugmakers of a similar size is 22.3×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far14.9×12.8×21.0×
202516.9×11.9×17.1×
202412.4×10.1×17.4×
202312.9×10.4×12.9×
202212.0×6.7×12.4×
20219.6×8.8×11.2×
20208.9×8.3×12.8×
201910.4×10.2×13.3×
201810.1×7.6×11.9×
20177.7×5.0×8.2×
20165.4×5.4×7.8×
20158.2×8.1×15.8×
201414.1×14.1×47.0×
201342.4×17.3×42.6×
201216.5×9.8×17.4×
20119.4×8.6×12.2×
20109.8×8.8×11.1×

Against its peers

Companies in Drug Manufacturers - General nearest Gilead Sciences' size, closest first, today.

CompanyPrice to free cash flow
GILDGilead Sciences14.9×
PFEPfizer15.6×
AMGNAmgen23.3×
BMYBristol-Myers Squibb11.0×
MRKMerck22.3×
ABBVAbbVie27.7×
JNJJohnson & Johnsonn/m
BIIBBiogen13.7×
LLYEli Lilly and65.9×
Peer median22.3×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Gilead Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.